Company profile JSPR
After 38 days of this quarter the interest is at 61.0. Based on that we can calculate that during remaining 53 days it will total up to 146.0. Jasper Therapeutics expected interest is significantly lower compared to same quarter last year (-40.2%) but similar to previous quarter.
| Year | Q1 | Q2 | Q3 | Q4 |
|---|---|---|---|---|
| 2019 | 14 | 0 -100.0% QoQ | 16 inf% QoQ | 58 262.5% QoQ |
| 2020 | 55 292.9% YoY -5.2% QoQ | 49 inf% YoY -10.9% QoQ | 41 156.2% YoY -16.3% QoQ | 75 29.3% YoY 82.9% QoQ |
| 2021 | 46 -16.4% YoY -38.7% QoQ | 93 89.8% YoY 102.2% QoQ | 78 90.2% YoY -16.1% QoQ | 216 188.0% YoY 176.9% QoQ |
| 2022 | 87 89.1% YoY -59.7% QoQ | 87 -6.5% YoY 0.0% QoQ | 79 1.3% YoY -9.2% QoQ | 60 -72.2% YoY -24.1% QoQ |
| 2023 | 244 180.5% YoY 306.7% QoQ | 123 41.4% YoY -49.6% QoQ | 84 6.3% YoY -31.7% QoQ | 113 88.3% YoY 34.5% QoQ |
| 2024 | 61 -75.0% YoY -46.0% QoQ | - | - | - |
The average 5 years interest of Jasper Therapeutics was 6.46 per week. The last year interest of Jasper Therapeutics compared to the last 5 years has changed by 37.46%. This is something to be checked. The last year interest is quite higher compared to 5 years ago. It has increased by 274.68%.
There is not enough data for Jasper Therapeutics Jasper Therapeutics clinical-stage biotechnology to provide analysis
There is not enough data for Jasper Therapeutics Jasper Therapeutics clinical-stage biotechnology to provide correlation calculation
There is not enough data for Jasper Therapeutics Jasper Therapeutics clinical-stage biotechnology to provide analysis
After 38 days of this quarter the interest is at 0.0. Based on that we can calculate that during remaining 53 days it will total up to 0.0. briquilimab expected interest is significantly lower compared to previous quarter (-100.0%) and same quarter last year (-100.0%).
| Year | Q1 | Q2 | Q3 | Q4 |
|---|---|---|---|---|
| 2019 | 59 | 111 88.1% QoQ | 160 44.1% QoQ | 20 -87.5% QoQ |
| 2020 | 98 66.1% YoY 390.0% QoQ | 32 -71.2% YoY -67.3% QoQ | 74 -53.8% YoY 131.2% QoQ | 142 610.0% YoY 91.9% QoQ |
| 2021 | 139 41.8% YoY -2.1% QoQ | 117 265.6% YoY -15.8% QoQ | 138 86.5% YoY 17.9% QoQ | 92 -35.2% YoY -33.3% QoQ |
| 2022 | 40 -71.2% YoY -56.5% QoQ | 0 -100.0% YoY -100.0% QoQ | 98 -29.0% YoY inf% QoQ | 37 -59.8% YoY -62.2% QoQ |
| 2023 | 148 270.0% YoY 300.0% QoQ | 208 inf% YoY 40.5% QoQ | 97 -1.0% YoY -53.4% QoQ | 75 102.7% YoY -22.7% QoQ |
| 2024 | 0 -100.0% YoY -100.0% QoQ | - | - | - |
The average 5 years interest of briquilimab was 7.25 per week. The last year interest of briquilimab compared to the last 5 years has changed by 32.83%. This is something to be checked. The last year interest is quite higher compared to 5 years ago. It has increased by 30.14%.
After 39 days of this quarter the interest is at 93.0. Based on that we can calculate that during remaining 52 days it will total up to 217.0. hematopoietic stem cell transplantation expected interest is significantly lower compared to previous quarter (-52.2%) but similar to same quarter last year.
| Year | Q1 | Q2 | Q3 | Q4 |
|---|---|---|---|---|
| 2019 | 174 | 468 169.0% QoQ | 415 -11.3% QoQ | 352 -15.2% QoQ |
| 2020 | 406 133.3% YoY 15.3% QoQ | 300 -35.9% YoY -26.1% QoQ | 202 -51.3% YoY -32.7% QoQ | 293 -16.8% YoY 45.0% QoQ |
| 2021 | 290 -28.6% YoY -1.0% QoQ | 188 -37.3% YoY -35.2% QoQ | 261 29.2% YoY 38.8% QoQ | 283 -3.4% YoY 8.4% QoQ |
| 2022 | 447 54.1% YoY 58.0% QoQ | 414 120.2% YoY -7.4% QoQ | 200 -23.4% YoY -51.7% QoQ | 193 -31.8% YoY -3.5% QoQ |
| 2023 | 275 -38.5% YoY 42.5% QoQ | 395 -4.6% YoY 43.6% QoQ | 241 20.5% YoY -39.0% QoQ | 454 135.2% YoY 88.4% QoQ |
| 2024 | 93 -66.2% YoY -79.5% QoQ | - | - | - |
The average 5 years interest of hematopoietic stem cell transplantation was 24.31 per week. The last year interest of hematopoietic stem cell transplantation compared to the last 5 years has changed by 10.9%. The interest for hematopoietic stem cell transplantation is seasonal. The last year interest is comparable to 5 years ago. It has changed only by -12.21%.
After 39 days of this quarter the interest is at 348.0. Based on that we can calculate that during remaining 52 days it will total up to 812.0. That appears to be equal to previous quarter and same quarter last year.
| Year | Q1 | Q2 | Q3 | Q4 |
|---|---|---|---|---|
| 2019 | 539 | 711 31.9% QoQ | 475 -33.2% QoQ | 679 42.9% QoQ |
| 2020 | 768 42.5% YoY 13.1% QoQ | 588 -17.3% YoY -23.4% QoQ | 477 0.4% YoY -18.9% QoQ | 564 -16.9% YoY 18.2% QoQ |
| 2021 | 851 10.8% YoY 50.9% QoQ | 780 32.7% YoY -8.3% QoQ | 675 41.5% YoY -13.5% QoQ | 681 20.7% YoY 0.9% QoQ |
| 2022 | 827 -2.8% YoY 21.4% QoQ | 781 0.1% YoY -5.6% QoQ | 551 -18.4% YoY -29.4% QoQ | 720 5.7% YoY 30.7% QoQ |
| 2023 | 897 8.5% YoY 24.6% QoQ | 777 -0.5% YoY -13.4% QoQ | 554 0.5% YoY -28.7% QoQ | 825 14.6% YoY 48.9% QoQ |
| 2024 | 348 -61.2% YoY -57.8% QoQ | - | - | - |
The average 5 years interest of gene therapy was 53.9 per week. The last year interest of gene therapy compared to the last 5 years has changed by 7.37%. The interest for gene therapy is seasonal. The last year interest is comparable to 5 years ago. It has changed only by 10.84%.
Google Trends for chronic spontaneous urticaria treatment
Not enough data for reliable calculations!
There is not enough data for chronic spontaneous urticaria treatment to provide analysis
There is not enough data for chronic spontaneous urticaria treatment to provide correlation calculation
There is not enough data for chronic spontaneous urticaria treatment to provide analysis
There is not enough data for lower risk myelodysplastic syndrome therapy to provide analysis
There is not enough data for lower risk myelodysplastic syndrome therapy to provide correlation calculation
There is not enough data for lower risk myelodysplastic syndrome therapy to provide analysis
There is not enough data for stem cell transplantation conditioning regimens to provide analysis
There is not enough data for stem cell transplantation conditioning regimens to provide correlation calculation
There is not enough data for stem cell transplantation conditioning regimens to provide analysis
There is not enough data for ex-vivo gene therapy to provide analysis
There is not enough data for ex-vivo gene therapy to provide correlation calculation
There is not enough data for ex-vivo gene therapy to provide analysis
There is not enough data for engineered hematopoietic stem cells to provide analysis
There is not enough data for engineered hematopoietic stem cells to provide correlation calculation
There is not enough data for engineered hematopoietic stem cells to provide analysis
There is not enough data for Redwood City California biotech company. to provide analysis
There is not enough data for Redwood City California biotech company. to provide correlation calculation
There is not enough data for Redwood City California biotech company. to provide analysis